

**REGISTRATION FORM****Deadline for receipt of early bird registration is May 16, 2008**

All requested information must be provided to process registration.  
All Fees are in U.S. Dollars.

**REGISTRANT INFORMATION**

First name \_\_\_\_\_

Last name \_\_\_\_\_

Nickname for badge \_\_\_\_\_

**Professional degree(s)** (please list one): \_\_\_\_\_

a. MD b. PhD c. MD, PhD d. RN e. DO f. Other: \_\_\_\_\_

Title \_\_\_\_\_

Organization \_\_\_\_\_

Address 1 \_\_\_\_\_

Address 2 \_\_\_\_\_

City \_\_\_\_\_

State/Province \_\_\_\_\_ Zip code + 4 \_\_\_\_\_

If outside the U.S., country/city code: \_\_\_\_\_

Country \_\_\_\_\_

Phone (\_\_\_\_) \_\_\_\_\_ Fax (\_\_\_\_) \_\_\_\_\_

E-mail address \_\_\_\_\_

Special Needs. (Dietary, accessibility, etc.) \_\_\_\_\_

1. I require a CME certificate for my attendance at this meeting. \_\_\_\_\_

2. I consider myself primarily (please list one): \_\_\_\_\_

a. Clinician b. Educator c. Scientist d. Other: \_\_\_\_\_

3. My work is best described as (please list one): \_\_\_\_\_

a. Endocrinologist b. Nuclear Medicine Physician c. Surgeon

d. Internal medicine e. Family Medicine f. Oncologist

g. Other: \_\_\_\_\_

4. My place of work is (please list one): \_\_\_\_\_

a. Academic b. Private practice c. Administration

d. Hospital e. Government/military f. Corporate/industry

g. Managed care h. Other \_\_\_\_\_

5. In case of emergency, please contact:

Name \_\_\_\_\_

Daytime Phone \_\_\_\_\_

Evening Phone \_\_\_\_\_

6. Meet the Professor Luncheon Workshops (please check one workshop per day – same topics offered each day): **NOTE: Limited seating available each day – two workshop selections will be assigned where possible.)**

Friday, July 11

\_\_\_\_ MTP 1: Neck US for thyroid Nodules, DTC, &amp; lymph node metastases

\_\_\_\_ MTP 2: DTC &amp; MTC Molecular-based therapy and clinical trials

\_\_\_\_ MTP 3: Management of DTC Distant Metastases

\_\_\_\_ MTP 4: TSH Suppression During DTC Follow-up

\_\_\_\_ MTP 5: Management of Low Risk DTC Patients

Saturday, July 12

\_\_\_\_ MTP 1: Neck US for thyroid Nodules, DTC, &amp; lymph node metastases

\_\_\_\_ MTP 2: DTC &amp; MTC Molecular-based therapy and clinical trials

\_\_\_\_ MTP 3: Management of DTC Distant Metastases

\_\_\_\_ MTP 4: TSH Suppression During DTC Follow-up

\_\_\_\_ MTP 5: Management of Low Risk DTC Patients

**FEE & PAYMENT INFORMATION**

7. Registration Fees (please circle applicable fees):  
(Registration fee includes lunches and meeting materials.)

	EARLY BIRD (RECEIVED BY May 16)	DISCOUNTED (received by June 13)	FULL FEE (received after June 13)
(M) ATA MEMBER	\$450	\$500	\$550
(N) NON-MEMBER	\$550	\$600	\$650
(A) FELLOWS/STUDENTS/RA	\$125	\$150	\$175
(F) FACULTY/SPEAKER	\$0	\$0	\$0

\*With Verification of status. Please fax a letter from your program director to 703-998-8893 or by e-mail to [thyroid@thyroid.org](mailto:thyroid@thyroid.org).

8. TOTAL FEES  
Registration TOTAL \$ \_\_\_\_\_

9. Submission and Payment — Checks and money orders for registration payable to the American Thyroid Association in U.S. dollars drawn on a U.S. bank.

MasterCard  VISA  American Express

Card number \_\_\_\_\_

Expiration date (month/year) \_\_\_\_\_

Print cardholder's name \_\_\_\_\_

Signature \_\_\_\_\_

**REGISTER ON-LINE** at the secure ATA web site [www.thyroid.org](http://www.thyroid.org).

**FAX** your completed form with credit card payment (no checks or money orders) to 678-341-3081. If you FAX, DO NOT MAIL, you risk duplicate charges.

**MAIL** your completed registration form with payment to: ATA Registration, c/o QMS, 6840 Meadowridge Court, Alpharetta, GA 30005. Phone 678-341-3056.

**REFUND POLICY:** Refund requests must be submitted in writing. Requests submitted by fax or e-mail before June 27, 2008 will receive a registration refund less a 50% processing fee. No refunds will be made if submitted after June 27, 2008. Refunds will be processed 30 days after the meeting. E-mail: [thyroid@thyroid.org](mailto:thyroid@thyroid.org) Please keep a copy of this form.

**CHAIRS – FACULTY – PROGRAM COMMITTEE****PROGRAM CHAIRS**

Richard Kloos, MD  
Co-Director, Thyroid Cancer Unit  
Division of Endocrinology and  
Nuclear Medicine  
*The Ohio State University Medical  
School*

Ernest L. Mazzaferri, MD  
Professor Emeritus  
*Ohio State University*

Professor of Medicine  
*University of Florida*

**FACULTY**

David S. Cooper, MD  
Director, Division of Endocrinology  
*Sinai Hospital of Baltimore*

Professor of Medicine  
*Johns Hopkins University School of  
Medicine*

Gerard M. Doherty, MD  
Professor and Section Head,  
General Surgery  
Chief, Division of Endocrine  
Surgery  
*The University of Michigan Health  
System*

Douglas B. Evans, MD  
Professor and Chief, Endocrine/  
Pancreatic Surgery  
*University of Texas M. D. Anderson  
Cancer Center*

Hossein Gharib, MD  
Professor, Department of  
Endocrinology  
*Mayo Clinic*

Bryan R. Haugen, MD  
Professor of Medicine and  
Pathology  
Division Head  
*University of Colorado Health Sciences  
Center*

Stephanie L. Lee, MD, PhD  
Professor and Director of  
Endocrine Clinics  
*Boston University Medical Center*

Susan J. Mandel, MD  
Associate Professor and Chief for  
Clinical Affairs, Division of  
Endocrinology  
*University of Pennsylvania School of  
Medicine*

Jeffrey F. Moley, MD  
Professor and Chief,  
Endocrinology and Oncologic  
Surgery  
*Washington University School of  
Medicine*

Matthew D. Ringel, MD  
Associate Professor of  
Medicine  
*The Ohio State University*

Steven I. Sherman, MD  
Professor and Chair,  
Department of Endocrine  
Neoplasia and Hormonal  
Disorders  
*University of Texas M. D. Anderson  
Cancer Center*

David L. Steward, MD  
Associate Professor  
Department of Otolaryngology,  
College of Medicine  
*University of Cincinnati*

R. Michael Tuttle, MD  
Associate Professor of  
Medicine  
*Memorial Sloan-Kettering Cancer  
Center*

Samuel A. Wells, Jr., MD  
Professor  
*Washington University School of  
Medicine*

**PROGRAM COMMITTEE**

Gerard M. Doherty, MD  
*The University of Michigan Health  
System*

Stephanie L. Lee, MD, PhD  
*Boston University Medical Center*

Susan J. Mandel, MD  
*University of Pennsylvania School  
of Medicine*

**ATA STAFF**

Barbara "Bobbi" Smith, CAE  
*Executive Director*

Adonia Calhoun Coates, CMP  
*Director of Meetings and Program  
Services*

Jared Hoke  
*Associate, Administration and  
Publications*

PRESORTED  
FIRST-CLASS  
U.S. POSTAGE  
**PAID**  
MERRIFIELD, VA  
PERMIT NO. 1228


American Thyroid Association  
6066 Leesburg Pike  
Suite 550  
Falls Church, VA 22041

**SAVE THE DATES:**

79<sup>TH</sup> ANNUAL MEETING OF THE ATA  
OCTOBER 1-5, 2008  
CHICAGO, IL

2009 ATA NATIONAL FRONTIERS IN  
THYROID CANCER WORKSHOP  
JANUARY 22-25, 2009  
MIAMI, FL

Visit [www.thyroid.org](http://www.thyroid.org) for meeting  
information and updates.

**FRONTIERS IN THYROID CANCER:  
ATA GUIDELINES IN CLINICAL PRACTICE**

BOSTON, MASSACHUSETTS **JULY 11-12, 2008**

**BRIEF DESCRIPTION OF ACTIVITY**

The incidence of thyroid cancer has been rising for the past three decades, provoking new ideas and controversy regarding the diagnosis and initial management of thyroid cancer, especially for small papillary thyroid carcinomas. For example, recent studies have shown that although patients with papillary thyroid microcarcinoma have a generally excellent prognosis, an important minority develop metastases and have recurrent disease, an observation that has provoked considerable debate. The American Thyroid Association evidence-based Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Carcinoma published in 2006 have sparked much interest in practitioners. Over 25,000 free copies of the guidelines were downloaded from the American Thyroid Association website between 2006 and 2007, underscoring the educational need physicians have for understanding the diagnosis and treatment of thyroid cancer. The speakers at the National Thyroid Cancer Workshop are the principal authors of the guidelines and will present the latest thinking on this subject.

**CME ACCREDITATION**

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The Ohio State University Medical Center and the American Thyroid Association. The Ohio State University Medical Center is accredited by the ACCME to provide continuing medical education for physicians.



The Ohio State University Medical Center, Center for Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. The Ohio State University Medical Center designates this educational activity for a maximum of 19 *AMA PRA Category 1 Credits™*. Physicians should only claim credit commensurate with the extent of their participation in the activity.

**CME NOTICES**

As a sponsor accredited by the ACCME, The Ohio State University Medical Center must ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities. All faculty participating in a sponsored activity are expected to disclose to the provider any relevant personal financial interest or other relationship involving themselves or their spouse/partner within the last 12 months with any proprietary entity producing health care goods or services (excluding nonprofit or government organizations) related to the content of the activity.

The intent of this disclosure is not to prevent a faculty contributor/speaker with a significant financial or other relationship from making the presentation, but rather to identify and resolve any conflicts of interest that may control the content of the activity. Faculty must also disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products.

Specific disclosure will be made to participants prior to the educational activity. *Audio taping or videotaping is prohibited.*



**TARGET AUDIENCE**

The importance of understanding and education of endocrinologists, surgeons, nuclear medicine physicians, oncologists, and respective subspecialty fellows on the management of thyroid cancer indicate a need for this two-day workshop.

**EDUCATIONAL DESIGN**

The ATA provides outstanding leadership in thyroidology by promoting excellence and innovation in clinical care, research, education and public advocacy. The National Thyroid Cancer Workshop features interactive sessions, innovative talks on cutting-edge topics and panel discussions. The workshop offers state-of-the-art information and unparalleled networking opportunities.

Upon completion of this conference, participants should be able to:

- Employ in their practice recent developments in the management of thyroid cancer and integration of new diagnostic and followup paradigms and the latest thyroid cancer therapies;
- Integrate changes in treatment that result from the evolving demography of thyroid cancer;
- Recognize the pathophysiology of thyroid cancer as it relates to new thyroid cancer drug therapies;
- Recognize and utilize, as necessary and appropriate, new drugs in the management of DTC and MTC.

**MEETING REGISTRATION**

*Space is limited – Register early!*

**REGISTER ONLINE** at the secure ATA website [www.thyroid.org](http://www.thyroid.org).

**FAX** your completed form with credit card payment (no checks or money orders) to 678-341-3081. If you FAX, DO NOT MAIL, you risk duplicate charges.

**MAIL** your completed registration form with payment to:

ATA Registration, c/o QMS, 6840 Meadowridge Court, Alpharetta, GA 30005. Phone 678-341-3056.

**ADA:** To request reasonable accommodations for a disability, please notify [thyroid@thyroid.org](mailto:thyroid@thyroid.org) in writing at least two weeks prior to the conference.

**HOTEL RESERVATIONS**

*Group rate cut-off date:* Friday, June 27, 2008.

A block of rooms has been reserved for the convenience of our attendees. Please call the Boston Park Plaza Hotel directly at (617) 426-2000 to make your reservation. Indicate that you are attending the ATA meeting to receive the group rate (\$189 per night, single or double, plus tax.

**PROGRAM HIGHLIGHTS**

FRIDAY, JULY 11	SESSION MODERATORS: RICHARD KLOOS & ERNEST MAZZAFERRI	FACULTY	SESSION CHAIR
7:45 am	Welcome and ATA Guideline Comments	David Cooper	
8:00 am – 8:30 am	Changing Demographics in Thyroid Cancer: Impact on Management	Ernest Mazzaferri	
8:30 am – 9:00 am	Thyroid Nodules: Diagnostic & Therapeutic Dilemmas	Hossein Gharib	
9:00 am – 9:30 am	Preoperative & Initial Surgical Management of DTC: Extent of Thyroid and Lymph Node Surgery	Gerard Doherty	
9:30 am – 10:00 am	Postoperative I-131 Remnant Ablation & therapy: Risk & Benefits, I-131 Dosimetry vs. Empiric Therapy	Bryan Haugen	
10:00 am – 10:30 am	BREAK (outside main meeting room)		
10:30 am – 11:00 am	New Paradigms and Problems in the Follow-up of DTC: US, Tg, and imaging	Martin Schlumberger	
11:00 am – 12:00 noon	Panel Discussion Case Initial Management Low and high Risk Tumors	Gerard Doherty Stephanie Lee Ernest Mazzaferri	David Cooper
12:00 noon – 1:00 pm	Meet the Professor Sessions based on Case Studies with LUNCH		
	MTP1: Neck US for Thyroid Nodules, DTC, & Lymph Node Metastases	Susan Mandel	
	MTP2: DTC & MTC Molecular-Based therapy and clinical trials	Matthew Ringel	
	MTP3: Management of DTC Distant Metastases	R. Mike Tuttle	
	MTP4: TSH Suppression During DTC Follow-up	David Cooper	
	MTP5: Management of Low Risk DTC Patients	Stephanie Lee	
1:00 pm – 2:00 pm	Debate: Which thyroid Nodules Should Undergo FNA	Susan Mandel Bryan Haugen	Richard Kloos
2:00 pm – 3:00 pm	Debate: Prophylactic Central Neck Dissection in PTC	Gerard Doherty David Steward	Ernest Mazzaferri
3:00 pm – 3:30 pm	BREAK (in the Exhibit Hall)		
3:30 pm – 4:30 pm	Debate: Radioiodine Ablation for Low Risk PTC	Ernest Mazzaferri R. Mike Tuttle	Matthew Ringel
4:30 pm – 5:30 pm	Panel Discussion Case Management Distant Metastases	Jeffrey Moley Martin Schlumberger Matthew Ringel	Steven Sherman
5:30 pm – 6:00 pm	Questions & Answers	Bryan Haugen	
6:00 pm	Adjourn		

SATURDAY, JULY 11	SESSION MODERATORS: RICHARD KLOOS & ERNEST MAZZAFERRI	FACULTY	SESSION CHAIR
7:45 am	Welcome and ATA Guideline Comments	Richard Kloos	
8:00 am – 8:30 am	Anaplastic Thyroid Cancer	Steven Sherman	
8:30 am – 9:30 am	Panel: Observation vs Resection of Persistent DTC Lymph Node Metastases	Jeffrey Moley Martin Schlumberger Douglas Evans Hossein Gharib	David Steward
9:30 am – 10:00 am	Special Problems: Managing DTC during Pregnancy and in the Elderly Patients.	Steven Sherman	
10:00 am – 10:30 am	BREAK (in the Exhibit Hall)		
10:30 am – 11:30 am	Panel: High Serum Tg levels and Negative Whole Body Scans	David Steward Hossein Gharib Ernest Mazzaferri	Bryan Haugen
11:30 am – 12:00 Noon	When to stop treating with radioiodine	R. Mike Tuttle	
12:00 noon – 1:00 pm	Meet the Professor Sessions based on Case Studies with LUNCH		
	MTP1: Neck US for thyroid Nodules, DTC, & Lymph Node Metastases	Susan Mandel	
	MTP2: DTC & MTC Molecular-Based Therapy and Clinical Trials	Steven Sherman	
	MTP3: Management of DTC Distant Metastases	R. Mike Tuttle	
	MTP4: TSH Suppression During DTC Follow-up	David Cooper	
	MTP5: Management of Low Risk DTC Patients	Stephanie Lee	
1:00 pm – 1:30 pm	MTC Genotype-Phenotype Correlations and Their Natural History	Richard Kloos	
1:30 pm – 2:00 pm	Prophylactic Surgery for Medullary Thyroid Cancer: Timing & Outcome	Douglas Evans	
2:00 pm – 2:30 pm	Therapeutic Surgery for MTC: Pre-Operative Evaluation and Extent of Surgery	Jeffrey Moley	
2:30 pm – 3:00 pm	Persistent & Recurrent MTC: Evaluation and Clinical Decision Making	Martin Schlumberger	
3:00 pm – 3:30 pm	BREAK (in the Exhibit Hall)		
3:30 pm – 4:00 pm	Targeting MTC for Molecular-Based Therapy: An Overview of Phase I and II Trials	Samuel Wells	
4:00 pm – 4:30 pm	MEN 2 Associated Pheochromocytoma and Hyperparathyroidism	Douglas Evans	
4:30 pm – 5:30 pm	Panel Discussion Case Management of MTC	Samuel Wells Hossein Gharib Douglas Evans	Richard Kloos
5:30 pm – 6:00 pm	Questions & Answers	Samuel Wells	
6:00 pm	Adjourn		

**LOCATION AND GENERAL INFORMATION**

**LOCATION**

Boston Park Plaza Hotel  
64 Arlington Street  
Boston, Massachusetts 02116  
(617) 426-2000

**HOTEL RESERVATIONS**

Group rate of \$189 per night, plus tax. Cut-off date for group rate is Friday, June 27, 2008.

**TELEPHONE**

(617) 426-2000. Make your reservation at the Boston Park Plaza Hotel in Massachusetts.

**TRAVEL INFORMATION.**

Indicate that you are with the ATA National Thyroid Cancer Workshop to receive the group rate.

**AMERICANS WITH DISABILITIES ACT (ADA)**

The ATA fully complies with the legal requirements of the ADA and the rules and regulations thereof.

**EXHIBIT HALL**

Exhibitors will share valuable information on the latest products and developments from pharmaceutical, laboratory, diagnostic, publication, patient education and professional organizations.

**FEES**

<i>(ALL FEES ARE IN US DOLLARS; ALL DATES ARE 2008):</i>			
DEADLINES:	EARLY BIRD- MAY 16	DISCOUNTED- JUNE 13	FULL FEE- AFTER JUNE 13
ATA Members .....	\$450.00 .....	\$500.00 .....	\$550.00
Non-members .....	\$550.00 .....	\$600.00 .....	\$650.00
Fellows* .....	\$125.00 .....	\$150.00 .....	\$175.00
* With verification of status			

*The registration fee includes instructional materials, lunch and refreshment breaks. Foreign payment must be made by credit card or with a U.S. Dollar World Money Order.*

**REFUND POLICY**

Refund requests must be submitted in writing. Requests submitted by fax or e-mail before June 27, 2008 will receive a registration refund less a 50% processing fee. No refunds will be made if submitted after June 27, 2008. Refunds will be processed 30 days after the meeting. Fax number: 703-998-8893. E-mail: [thyroid@thyroid.org](mailto:thyroid@thyroid.org)

**FOR FURTHER INFORMATION**

**Confirmation of Registration:** 678-341-3056  
**Fax Registration:** 678-341-3081  
The ATA national headquarters is at 6066 Leesburg Pike, Suite 550 Falls Church, VA 22041.  
703-998-8890; [thyroid@thyroid.org](mailto:thyroid@thyroid.org)